Chen et al. demonstrated hypoxia-induced CXCR4-mediated immunosuppression under sorafenib pressure, propelling the #1 tumor microenvironment cluster and transitioning resistance mechanisms from tumor-autonomous to niche co-evolution models (Chen et al., 2015). This evidence concerns the gene CXCR4 and neoplasm.